Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: Results from the phase 2 international study

William G. Wierda, Swaminathan Padmanabhan, Geoffrey W. Chan, Ira V. Gupta, Steen Lisby, Anders Österborg

Research output: Contribution to journal › Article › peer-review

153 Scopus citations

Fingerprint

Dive into the research topics of 'Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: Results from the phase 2 international study'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemistry